- Details
- Antonina Mitrofanova delves into her team's research published in Nature Communications. The study uncovers the NME2 and MYC programs as pivotal markers of enzalutamide resistance in castration-resistant prostate cancer (CRPC). Dr. Mitrofanova's team embarked on this journey following observations that patients with elevated MYC levels showed increased resistance to androgen receptor signal inhibi...
|
- Details
- Tanya Stoyanova discusses research on Trop2's role in prostate cancer, published in Nature Scientific Reports. Collaborating with Drs. Michael Liss and Jim Brooks, the study reveals Trop2 as a high-potential therapeutic target due to its overexpression in various epithelial cancers, including prostate cancer, where it's linked to aggressive behavior. Their work, validated in a large patient cohort...
|
- Details
- Andrea Miyahira and Alex Wyatt discuss a study on de novo metastatic prostate cancer, revealing its genomic complexity through multiregion sampling. Published in Nature Cancer, the research highlights the polyclonality of the disease and its implications for clinical genotyping. By examining multiple regions from patients' prostates and lymph nodes, the study uncovers significant genomic heterogen...
|
- Details
- Massimo (Max) Loda discusses his team’s research on the role of the microenvironment in prostate cancer progression, published in Nature Communications. The study focuses on the stroma's significance in prostate carcinogenesis. Utilizing mouse models and human tumors, they performed single-cell RNA sequencing to analyze stromal cells in different stages of prostate cancer. The research revealed di...
|
- Details
- Andrea Miyahira hosts Andrew Goldstein to discuss his group's research on prostate cancer, published in Nature Cell Biology. Dr. Goldstein, along with his team, including grad students Jenna Giafaglione and Preston Crowell, explores the metabolic processes influencing prostate cancer's response to anti-androgen treatment. Their study reveals that basal and luminal cells in the prostate have distin...
|
- Details
- Andrea Miyahira hosts Johann De Bono to discuss his group's paper on reversing prostate cancer therapy resistance by targeting myeloid chemotaxis. Dr. De Bono, with contributions from his team, including Christina Guo and Adam Sharp, explores the role of inflammation in prostate cancer. The study focuses on how stressed cancer cells attract inflammatory cells, which can then support tumor growth a...
|
- Details
- Andrea Miyahira hosts Ping Mu to discuss his group's research on prostate cancer resistance to anti-androgens. Dr. Mu's study, published in Oncogene, focuses on the gene UBE2J1, identified as a key E2 ubiquitin-conjugating enzyme regulating Androgen Receptor (AR) degradation. He explains that despite advancements in anti-androgen therapies like enzalutamide, resistance remains a significant challe...
|
- Details
- Andrea Miyahira interviews Mayuko Kanayama about her team's research on a HOXB13 variant linked to aggressive prostate cancer in African ancestry populations. Published in European Urology, their study focuses on the HOXB13 stop-loss germline variant X285K, prevalent in West African ancestry, including Nigeria, Senegal, and Ghana. This variant, associated with earlier diagnosis and higher Gleason...
|
- Details
- Asmaa El-Kenawi discusses her group's research on therapeutic resistance in cancer, particularly focusing on the role of methionine in driving resistance. Published in "Cancer Research," the study explores how cancer cells adapt to evade pyroptosis, a form of cell death. Dr. El-Kenawi, an assistant professor at Indiana University, explains that while many effective cancer therapies exist, resistan...
|
- Details
- Jindan Yu delves into her team's research on "Chemokine Receptor CXCR7 Activates Aurora Kinase A and Promotes Neuroendocrine Prostate Cancer Growth," published in the Journal of Clinical Investigation. Dr. Yu's study began with the observation that CXCR7, an atypical chemokine receptor, is upregulated in enzalutamide-resistant prostate cancer cells. The research reveals that CXCR7, unlike the bett...
|
